BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 16260852)

  • 21. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of interferon-gamma, interleukin-6, and tumor necrosis factor-alpha in the radiation response of patients diagnosed with locally advanced non-small-cell lung cancer and glioblastoma multiforme.
    Deniz ÇD; Gürbilek M; Koç M
    Turk J Med Sci; 2018 Feb; 48(1):117-123. PubMed ID: 29479968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
    Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
    Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
    BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
    De Vita F; Orditura M; Galizia G; Romano C; Roscigno A; Lieto E; Catalano G
    Chest; 2000 Feb; 117(2):365-73. PubMed ID: 10669676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative chemotherapy increases cytokine production after lung cancer surgery.
    Endo S; Sato Y; Hasegawa T; Tetsuka K; Otani S; Saito N; Tezuka Y; Sohara Y
    Eur J Cardiothorac Surg; 2004 Oct; 26(4):787-91. PubMed ID: 15450574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective suppression of cytokine secretion in patients with small-cell lung cancer.
    Fischer JR; Schindel M; Stein N; Lahm H; Gallati H; Krammer PH; Drings P
    Ann Oncol; 1995 Nov; 6(9):921-6. PubMed ID: 8624296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC).
    Karapanagiotou EM; Tsochatzis EA; Dilana KD; Tourkantonis I; Gratsias I; Syrigos KN
    Lung Cancer; 2008 Sep; 61(3):391-7. PubMed ID: 18342391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
    Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
    J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteopontin as a marker of weight loss in lung cancer.
    Karadag F; Gulen ST; Karul AB; Kilicarslan N; Ceylan E; Kuman NK; Cildag O
    Scand J Clin Lab Invest; 2011 Dec; 71(8):690-4. PubMed ID: 22017168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
    Zhang S; He L; Dai N; Guan W; Shan J; Yang X; Zhong Z; Qing Y; Jin F; Chen C; Yang Y; Wang H; Baugh L; Tell G; Wilson DM; Li M; Wang D
    Oncotarget; 2016 Nov; 7(47):77482-77494. PubMed ID: 27813497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.
    Mehtap O; Atesoglu EB; Tarkun P; Hacihanefioglu A; Dolasik I; Musul MM
    J Postgrad Med; 2014; 60(2):141-4. PubMed ID: 24823512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition?
    Alemán MR; Santolaria F; Batista N; de La Vega M; González-Reimers E; Milena A; Llanos M; Gómez-Sirvent JL
    Cytokine; 2002 Jul; 19(1):21-6. PubMed ID: 12200109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels.
    Liou LB
    Clin Exp Rheumatol; 2003; 21(4):437-44. PubMed ID: 12942694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.